Name: Juvmo (tavapadon) in Parkinson's disease: Base case
Published: 2026-09-27T21:44:59-04:00

Economic information and modeling report Budget impact model Results

Base case

2 evidence topics · 1 source

First-line treatment compared with levodopa at the placeholder price

“At the placeholder price of $15,000 per year, the average annual potential budget impact per patient treated was approximately $12,500 in year one and $20,200 in year five.” (opens the source at this quote in a new tab)
“At the placeholder price of $15,000 per year, 46% of the first-line candidate population could be treated with tavapadon before reaching the potential budget impact threshold of $821 million.” (opens the source at this quote in a new tab)

Add-on treatment compared with other dopamine agonists at the placeholder price

“Figure 7.2 illustrates the cumulative per-patient potential budget impact of tavapadon as add-on treatment with levodopa compared to other dopamine agonists over the five-year time horizon, assuming 20% uptake each year. At the placeholder price of $15,000 per year, the average annual potential budget impact per patient treated was approximately $8,600 in year one and $13,700 in year five.” (opens the source at this quote in a new tab)
“At the placeholder price of $15,000 per year, 59% of the candidate population for add-on treatment could be treated with tavapadon before reaching the potential budget impact threshold of $821 million.” (opens the source at this quote in a new tab)